Case studies
Better decisions, in real development programs
Anonymized results from sponsors who used PhaseV to prioritize assets, find the patients who respond, design stronger trials and choose the right sites.

ClinOps Optimizer
Trial Optimizer
Oncology
How Smarter Site Selection Saved a Phase 3 Lung Cancer Trial 9 Months and $30M
A Phase 3 lung cancer trial was set to miss its 24-month goal. Smarter sites and design cut 9 months, 33 sites and 95 patients.
$30Mestimated cost saved

ClinOps Optimizer
Pulmonology
How Causal ML Site Selection Nearly Halved Enrollment Time in Two Global COPD Trials
Two global Phase 3 COPD trials faced up to 3.8 years of enrollment. A causal ML site list cut the estimate to 1.95 years with 25 fewer sites.
1.95years to enroll, down from 3.8

Trial Optimizer
Infectious Disease
How AI-Optimized Adaptive Design Cut a Phase 3 Infectious Disease Trial by 6 Months
Simulating millions of designs found a Phase 3 adaptive trial that is 25% shorter with 9% fewer patients, saving $6.05M at about 90% power.
25%shorter trial

Trial Optimizer
Immunology
How Adaptive Enrichment Gave a Phase 2 Rheumatic Disease Trial 25% More Statistical Power
Simulation designed a Phase 2 rheumatic disease trial that focuses enrollment on likely responders, with a 25% gain in statistical power.
25%more statistical power

Response Optimizer
Metabolic
Rescuing a Failed Phase III Trial: Finding the Patients Who Respond to Oral Insulin
After a Phase III oral insulin trial missed its endpoint, causal ML found the responder subgroups. Oramed re-initiated a Phase III trial.

Response Optimizer
Neurology
How Finding the Right ALS Patients Led to a Smaller, Higher-Probability Phase 3 Trial
A progression model and a high-efficacy subgroup informed a Phase 3 ALS design with a smaller sample size and a higher probability of success.

Response Optimizer
Immunology
How a Lupus Prognostic Model Cut Variance 15% and Shrank the Next Trial
A lupus prognostic model cut variance by about 15%, equivalent to 92 fewer participants, and informed the client’s next trial design.
~15%variance reduction

Portfolio Optimizer
Metabolic
How a Top-5 Pharma Company Valued a Biotech Pipeline in 8 Weeks
A top-five pharma ranked a target biotech’s indications on causal evidence, market and feasibility in 8 weeks, saving over $1M in external spend.
8 wksto deliver insights

Portfolio Optimizer
Metabolic
What Causal Analysis Revealed About Weight Loss and Obesity-Related Disease
Causal analysis showed benefit appears only at very high weight loss and split weight-driven from direct drug effects.
ClinOps Optimizer
Portfolio Optimizer
Response Optimizer
Trial Optimizer
Hematology
Immunology
Infectious Disease
Metabolic
Nephrology
Neurology
Oncology
Pulmonology
Rare Disease